CMS approved transitional pass-through status for Anjeso, a once-daily intravenous analgesic intended for the management of moderate to severe pain in adults.
Three things to know:
1. The new reimbursement code for Anjeso is C9059. It is set to take effect July 1 for ASCs and hospital outpatient departments.
2. Baudax Bio announced the new pass-through status and commercial launch of Anjeso June 15.
3. Anjeso gained FDA approval earlier in the year, for use alone or in combination with non-steroidal anti-inflammatory drugs.